News
Ipsen charts $1.75bn course for Kartos acquisition
Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Oncology
ASCO 2026: Can a blood test spot cancer early? with Dr Peter...
Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Oncology
CAR-T has a geography problem
The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.
News
Moderna shows in vivo CAR-T hand in R&D update
At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.
News
Ibrance cleared in US for 'double-positive' breast cancer
Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
